Walder Wyss advised TECregen, as the Basel-based biotechnology company raised CHF 10 million in a seed financing round. The investor base Boehringer Ingelheim Venture Fund (BIVF) led the round in question, with participation from LifeSpan
Tags :sx1
Effective January 1st 2026, Riccardo Geiser (pictured) has rejoined Altenburger as a partner in the firm’s corporate/M&A team. Furthermore, he will integrate the firm’s Italian desk, advising on matters involving Switzerland
Walder Wyss officialised the promotion of Iliana Djagova (pictured right) to partner in the corporate and M&A team, and Matthias Lötscher (pictured left) to counsel in the banking & finance team, both
In December 2025, Oberson Abels officialised the opening of its new Bern office. In connection with the move, the firm welcomed Diego Clavadetscher (pictured), tax specialist and lecturer in VAT law at the University of Bern,
Vischer advised Relief, now MindMaze Therapeutics Holding, in connection with its acquisition of all shares in NeuroX Group, against issuance of new MMTX shares to complete their business combination by way of reverse merger.
Kellerhals Carrard advised the shareholders of GHZ Gewerbe und Handelszentrum Schlieren, as Swiss Life acquired all shares in the company. GHZ is the owner of the Wagi site in Schlieren, a business location hosting around 250
Kellerhals Carrard advised Gravis Robotics — a Zurich-based construction-tech company Founded in 2022 at ETH Zurich — throughout its USD 23 million financing round. IQ Capital and Zacua Ventures co-led the round in question, with further support from Pear
Kellerhals Carrard advised the existing ownership of globally active physical energy trading company Gunvor Group as members of it – together with members of the management – agreed to a management buy-out. Pursuant to the agreement,
Pestalozzi – together with the Orrick Paris Tech Studio – advised Zurich-based tech company Flexion Robotics throughout its USD 50 million series A financing round. The investor base DST Global Partners, NVentures (NVIDIA’s venture capital arm), redalpine,
Advestra advised Novartis, as the Basel-based pharma multinational placed notes in the aggregate principal amount of USD 6.0 billion. The issuance featured seven tranches of which six referring to fixed rate notes and one to floating
